Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Health CatalystHCAT +1.82%52 Days Sales Outstanding is 65.41 as of Jun. 2026, which is 6% below its 10-year median of 69.93. GuruFocus rates HCAT with a GF Score™ of 52/100 and a GF Value™ of $4.07 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 662 Healthcare Providers & Services companies, Health Catalyst ranks worse than 73.41% on this metric.
The historical rank and industry rank for Health Catalyst's Days Sales Outstanding or its related term are showing as below:
HCAT'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.93 Med: 69.93 Max: 85.17
Current: 72.11
During the past 9 years, Health Catalyst's highest Days Sales Outstanding was 85.17. The lowest was 63.93. And the median was 69.93.
HCAT's Days Sales Outstanding is ranked worse than 73.41% of 662
companies
in the Healthcare Providers & Services industry
Industry Median: 45.825
vs HCAT: 72.11
Health Catalyst's Days Sales Outstanding
declined
from Jun. 2025 (74.85) to Jun. 2026 (65.41).
Health Catalyst (NAS:HCAT) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Health Catalyst Days Sales Outstanding Related Terms
Health Catalyst Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Health Catalyst's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCAT vs DH, CCLD, OPRX: Days Sales Outstanding Comparison
For the Health Information Services subindustry, Health Catalyst's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Health Catalyst Days Sales Outstanding vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Health Catalyst's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Health Catalyst's Days Sales Outstanding falls into.
Health Catalyst Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Health Catalyst (HCAT) has a Days Sales Outstanding of 65.41 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Health Catalyst and its competitors. This is near median its historical median of 69.93. Over the past decade, Health Catalyst's Days Sales Outstanding has ranged from 63.93 to 85.17. According to the industry distribution chart, Health Catalyst ranks #486 out of 662 companies in the Healthcare Providers & Services industry, placing it in the top 73.4%.
Is Health Catalyst's Days Sales Outstanding too high?
Health Catalyst's current Days Sales Outstanding of 65.41 is near median its 10-year median of 69.93. Over the past 10 years, this metric has ranged from a low of 63.93 to a high of 85.17. The Healthcare Providers & Services industry median Days Sales Outstanding is 45.83. Health Catalyst's value of 65.41 is 42.7% above this industry median. Based on the distribution chart, Health Catalyst ranks #486 out of 662 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Health Catalyst has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Health Catalyst's Days Sales Outstanding compare to DH and CCLD?
According to the Healthcare Providers & Services industry distribution chart, Health Catalyst ranks #486 out of 662 companies for Days Sales Outstanding. This places Health Catalyst in the lower half of its industry. The industry median Days Sales Outstanding is 45.83. Health Catalyst's value of 65.41 is 42.7% above this benchmark. Historically, Health Catalyst's own Days Sales Outstanding has ranged from 63.93 to 85.17 over the past decade. While the company's 10-year median is 69.93 vs. the industry median of 45.83, Health Catalyst has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Healthcare Providers & Services company?
The median Days Sales Outstanding among Healthcare Providers & Services companies is 45.83, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Health Catalyst's current Days Sales Outstanding of 65.41 is 42.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Health Catalyst and its competitors. For the Healthcare Providers & Services industry, the median Days Sales Outstanding is 45.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Health Catalyst's current Days Sales Outstanding is 65.41, which is near median its own 10-year median of 69.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Health Catalyst stock overvalued right now?
Based on GuruFocus' analysis, Health Catalyst (HCAT) is currently considered Possible Value Trap. The stock's GF Value™ is $4.07, compared to a current price of $1.68 — trading 58.7% below its estimated fair value. The current Days Sales Outstanding is 65.41, which is near median its 10-year median of 69.93 and 42.7% above the Healthcare Providers & Services industry median of 45.83. Health Catalyst's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Health Catalyst (HCAT), the current Days Sales Outstanding is 65.41 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Health Catalyst (HCAT) Overvalued in 2026?
Based on GuruFocus' analysis, Health Catalyst stock appears to be undervalued.
The current stock price of $1.68 is trading 58.7% below its estimated GF Value™ of $4.07.
GuruFocus considers Health Catalyst to be Possible Value Trap.
Key valuation signals for HCAT:
Days Sales Outstanding: 65.41 (near median its 10-year median of 69.93)
GF Value™: $4.07 vs. price of $1.68 (58.7% below fair value)
Industry Position: 42.7% above the Healthcare Providers & Services median (#486 of 662)
No single metric tells the full story. See the HCAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platform, analytics applications and support services and generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
52GF Score
Get the complete analysis for HCAT
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCAT has been successfully added to your 
